Curated News
By: NewsRamp Editorial Staff
October 07, 2025
GeoVax CEO to Present Pipeline at ROTH Healthcare Conference
TLDR
- GeoVax's CEO will meet investors to showcase their advanced vaccine pipeline, offering potential investment advantages in biotech innovation.
- GeoVax's CEO will participate in structured 25-minute investor meetings to detail clinical trial progress and regulatory advancements for their vaccine candidates.
- GeoVax's vaccine development aims to improve global health by protecting vulnerable populations from infectious diseases and advancing cancer treatments.
- GeoVax is developing novel vaccines for mpox, COVID-19, and cancer therapies, with some candidates progressing directly to Phase 3 trials.
Impact - Why it Matters
This development matters because GeoVax is advancing multiple vaccine and immunotherapy candidates that address critical public health needs, including next-generation COVID-19 vaccines for immunocompromised patients, Mpox/smallpox preparedness vaccines, and innovative cancer therapies. The company's participation in a major investor conference signals important progress in their clinical programs and potential near-term catalysts. For patients, GeoVax's pipeline represents hope for more effective vaccines and cancer treatments, particularly for vulnerable populations who don't respond well to current options. For investors and the healthcare sector, successful development of these candidates could address significant market gaps while contributing to global health security against infectious disease threats and advancing oncology treatment options.
Summary
GeoVax Labs, Inc., a clinical-stage biotechnology company trading on Nasdaq under GOVX, has announced that its Chairman and CEO David Dodd will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Yale Club in New York City. This invite-only event connects innovative healthcare companies with institutional investors through 1-on-1 meetings and small group sessions, providing a platform for C-level executives to discuss their company's strategies and pipelines. Mr. Dodd will be available throughout the day to meet with investors and share updates on GeoVax's promising vaccine and immunotherapy pipeline, positioning the company for significant investor engagement during this prestigious healthcare conference.
The company's pipeline highlights three key developments that investors will be discussing. First is GEO-MVA, an MVA-based Mpox/smallpox vaccine that recently received favorable Scientific Advice from the European Medicines Agency and is positioned to support global preparedness and stockpile strategies. Second is GEO-CM04S1, GeoVax's multi-antigen COVID-19 vaccine currently undergoing evaluation in three Phase 2 clinical trials across various patient populations, including immunocompromised individuals and healthy adults. Third is Gedeptin®, the company's gene-directed enzyme prodrug therapy for solid tumors, with a planned Phase 2 trial in head and neck cancer, representing an innovative approach to oncology treatment that could address significant unmet medical needs in cancer care.
GeoVax's participation in this conference through the NEWMEDIAWIRE platform underscores the company's commitment to advancing novel vaccines against infectious diseases and therapies for solid tumor cancers. The company maintains a strong intellectual property portfolio with worldwide rights for its technologies and products, and investors can find more information about current clinical trial status and updates by visiting www.geovax.com. The ROTH conference's intensive 25-minute management-investor meeting format is specifically designed to provide institutional clients with extensive opportunities for interaction with executive management teams, delivering in-depth insights into each company's strategy and upcoming milestones that could drive future growth and market performance.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, GeoVax CEO to Present Pipeline at ROTH Healthcare Conference
